en · de · es
semax-notes.peptides6155.com › Topic › � ”发背景与监管地位 — Practical Notes

� ”发背景与监管地位 — Practical Notes

By Editorial Desk · published 2026-07-21 · last reviewed 2026-08-01 · Topic

A practical reference on ACTH(4-10): what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

研发背景与监管地位

当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应,Semax 属于这一路线。鼻内给药是其主要使用方式,俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上,样本规模与终点设置同西方试验惯例存在差异,国际同行对其临床证据的强度看法不一。

各国监管态度分化明显。俄罗斯按处方药管理,部分东欧国家留有使用记录;欧盟与美国未批准其作为药物上市,市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录,跨境携带则受目的地药品法规约束。

Semax Structure and Research Background

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.

Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.

Semax at a glance

PropertyValueNotes
结构类别线性合成七肽无环化结构,不含二硫键
氨基酸序列Met-Glu-His-Phe-Pro-Gly-ProN 端为甲硫氨酸
分子量约 814 Da游离碱形式的计算值
外观白色至类白色粉末具吸湿性
溶解性易溶于水亦可溶于甲醇等极性溶剂

Semax Background and Molecular Structure

Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.

The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.

Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.

Related pages on this site

Notes from published material

At the age of 14, Zverev entered qualifying at three different tournaments, including the 2011 Moselle Open on the ATP Tour, but lost all of his matches. He won his professional main draw debut against compatriot Christian Lichtenegger at a Futures event in Germany in August 2012. At the end of the year, he made his first professional final, finishing runner-up to Florian Reynet at an ITF $10K event in Florida. Zverev continued to focus on the juniors in 2013 and did not reach another pro-level final that year, but he did make his main draw debut on the ATP Tour in July, losing to Roberto Bautista Agut at his hometown tournament, the International German Open. He also made his ATP Challenger Tour debut, losing to Máximo González at the Meerbusch Challenger in August. After winning the boys' singles title at the 2014 Australian Open, Zverev shifted his focus to his professional career, only playing in pro events the rest of the year. Initially, he struggled on the pro tour, failing to qualify for the main draw at his first five events of the season. He did not win a main draw match until he recorded a single victory at the Heilbronner Neckarcup Challenger, his tenth event of the year. One of his losses was a retirement against his brother Mischa. Zverev made his first professional breakthrough in July when he won the Braunschweig Challenger for his first professional title, despite entering the tournament with just one career Challenger-level match win and no top 100 victories. Three of the players he defeated were in the top 100, including his first-round opponent No.

By September 1604, Dmitri I had gathered a force of 2,500 men, of whom 1,400 were Cossacks. Two thirds of these "cossacks", however, were in fact Ukrainian civilians, only 500 being professional Ukrainian Cossacks. On July 4, 1610, 4,000 Ukrainian Cossacks fought in the Battle of Klushino, on the side of the Polish-Lithuanian Commonwealth. They helped to defeat a combined Muscovite-Swedish army and facilitate the occupation of Moscow from 1610 to 1611, riding into Moscow with Stanisław Żółkiewski. The final attempt by King Sigismund and Wladyslav to seize the throne of Muscovy was launched on April 6, 1617. Although Wladyslav was the nominal leader, it was Jan Karol Chodkiewicz who commanded the Commonwealth forces. By October, the towns of Dorogobuzh and Vyazma had surrendered. But a defeat, when the counterattack on Moscow by Chodkiewicz failed between Vyasma and Mozhaysk, prompted the Polish-Lithuanian army to retreat. In 1618, Petro Konashevych-Sahaidachny continued his campaign against the Tsardom of Russia on behalf of the Cossacks and the Polish-Lithuanian Commonwealth. Numerous Russian towns were sacked, including Livny and Yelets. In September 1618, with Chodkiewicz, Konashevych-Sahaidachny laid siege to Moscow, but peace was secured.

Furthermore, it has been observed in many retrospective longitudinal studies that corticosteroid treatment does not seem to significantly prolong survival of the native liver or transplant-free survival.

Sources: en.wikipedia.org

Further detail

is 15 denarii per pound, while that of white pepper is seven, and of black, four." Pliny also complains, "There is no year in which India does not drain the Roman Empire of 50 million sesterces", and further moralises on pepper:

=== Proteomics === ETD is widely used in the analysis of protein and large peptides. Important post translational modifications including phosphorylation, glycosylation and disulfide linkages are all analyzed using ETD.

== Function == S100B is glial-specific and is expressed primarily by astrocytes, but not all astrocytes express S100B. It has been shown that S100B is only expressed by a subtype of mature astrocytes that ensheath blood vessels and by NG2-expressing cells. This protein may function in neurite extension, proliferation of melanoma cells, stimulation of Ca2+ fluxes, inhibition of PKC-mediated phosphorylation, astrocytosis and axonal proliferation, and inhibition of microtubule assembly. In the developing CNS it acts as a neurotrophic factor and neuronal survival protein. In the adult organism it is usually elevated due to nervous system damage, which makes it a potential clinical marker.

Sources: en.wikipedia.org

Frequently asked questions

Semax 在自然界中存在吗?

不存在。它是依据 ACTH 的一段序列人工设计的分子,天然蛋白质中找不到与之完全相同的七肽。名称属于研究代号,而非天然物质名。

它与 ACTH 的差别在哪里?

Semax 对应 ACTH 第 4 至第 10 位的片段,并在两端做了替换与延长,使其不再具备促肾上腺皮质激素的典型内分泌活性。这一改动同时改变了它在体内的稳定性与分布特征。

哪些地区可以合法获得?

俄罗斯将其列为处方药物,需要医生开具处方。多数其他国家把它当作研究化合物,不能作为药品销售或宣称疗效。具体合法性取决于当地法规。

What is semax?

Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.

Network